As previously mentioned, the current standard in ovarian cancer biomarkers primarily utilize CA125 as it offers good sensitivity at late stages of disease progression; however, it has limited sensitivity in early stage disease (stages I and II) [35,36,37,38]. Here, MUC16 is linked to ovarian cancer.